Arena Pharmaceuticals, Inc. (ARNA)
| Market Cap | 4.87B |
| Revenue (ttm) | 319,000 |
| Net Income (ttm) | -404.73M |
| Shares Out | 54.77M |
| EPS (ttm) | -7.39 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 1 |
| Last Price | $80.08 |
| Previous Close | $80.35 |
| Change ($) | -0.27 |
| Change (%) | -0.34% |
| Day's Open | 81.57 |
| Day's Range | 79.96 - 81.85 |
| Day's Volume | 420,084 |
| 52-Week Range | 32.95 - 90.19 |
Welcome back to our weekly series, Sc haeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry...
Arena Pharmaceuticals (ARNA) misses bottom-line estimates for fourth-quarter 2020. It initiates new study to evaluate etrasimod in patients with eosinophilic esophagitis.
Shares of Arena Pharmaceuticals (NASDAQ:ARNA) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 19.32% year over year to ($2.10...
SAN DIEGO--(BUSINESS WIRE)---- $ARNA #ArenaPharm--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the fourth quarter and full ye...
On Tuesday, February 23, Arena Pharmaceuticals (NASDAQ:ARNA) will release its latest earnings report. Check out Benzinga's preview to understand the implications.
Welcome back to our weekly series, Sc haeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry...
SAN DIEGO--(BUSINESS WIRE)--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on February 15, 2021, the Compensation Committee of its Board of Directors granted to eleven new emp...
SAN DIEGO--(BUSINESS WIRE)---- $ARNA #earnings--Arena Pharmaceuticals to Release Fourth Quarter & Full-Year 2020 Financial Results and Provide Corporate Update on February 23.
SAN DIEGO--(BUSINESS WIRE)-- #ArenaPharm--Industry veteran Garry Neil, MD named Board Chair. Nawal Ouzren, CEO of Sensorion named to Board.
Welcome back to our weekly series, Sc haeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry...
SAN DIEGO--(BUSINESS WIRE)---- $ARNA--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it has completed full enrollment of the Phase 3 ELEVATE UC 52 trial evaluating the safety ...
Welcome back to our weekly series, Sc haeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry...
SAN DIEGO--(BUSINESS WIRE)--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on January 15, 2021, the Compensation Committee of its Board of Directors granted to five new employ...
Welcome back to our weekly series, Sc haeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks over the past week, and look ahead to how the cannabis...
Welcome back to our weekly series, Sc haeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks over the past week, and look ahead to how the cannabis...
Arena Pharmaceuticals, Inc. (ARNA) CEO Amit Munshi Presents at 39th Annual J.P. Morgan Healthcare Conference (Transcript)
SAN DIEGO, Dec. 22, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi, the Company's President and Chief Executive Officer, is scheduled to pr...
SAN DIEGO, Dec. 18, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on December 15, 2020, the Compensation Committee of its Board of Directors granted to f...
SAN DIEGO, Dec. 11, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that data from the Phase 2b ADVISE trial evaluating the safety and efficacy of etrasimod, a ...
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead at the pot stocks to watch in ...
Arena Pharmaceuticals, Inc. (ARNA) CEO Amit Munshi Presents at 3rd Annual Evercore ISI HealthCONx Conference (Transcript)
SAN DIEGO--(BUSINESS WIRE)--Arena Pharmaceuticals announces the appointment of Paul D. Streck, M.D., as Senior Vice President, Clinical Development and Chief Medical Officer.
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead at the pot stocks to watch in ...
SAN DIEGO, Nov. 19, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on November 15, 2020, the Compensation Committee of its Board of Directors granted to 1...
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and we will look ahead at the pot stocks to w...
The biotech posted clinical trial data that left more to be desired.
Arena Pharmaceuticals (ARNA) beats bottom-line estimates for third-quarter 2020. Mid-stage atopic dermatitis study on etrasimod fails to meet primary endpoint but phase III study may start soon.
Arena Pharmaceuticals' (ARNA) CEO Amit Munshi on Q3 2020 Results - Earnings Call Transcript
Shares of Arena Pharmaceuticals (NASDAQ:ARNA) decreased 19.4% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share fell 15.75% over the past year...
SAN DIEGO, Calif., Nov. 9, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the third quarter ended Septembe...
SAN DIEGO, Nov. 9, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced topline results from the Phase 2b ADVISE clinical trial evaluating etrasimod, a highly select...
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks...
Arena Pharmaceuticals has an impressive pipeline of compounds, and its trials are progressing well now, despite the impact of COVID-19. After its equity offering in early June at $50 per share...
SAN DIEGO, Oct. 9, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will present new data from the Phase 2 OASIS trial and its open-label extension for its investigative drug ca...
Arena Pharmaceuticals, Inc. (ARNA) CEO Amit Munshi Presents at Jefferies Next Generation IBD Therapeutics Virtual Summit Call Transcript
Arena Pharmaceuticals, Inc. (ARNA) CEO Amit Munshi Presents at Cantor 2020 Global Virtual Healthcare Conference (Transcript)
Arena Pharmaceuticals, Inc.'s (ARNA) CEO Amit Munshi at H.C.
Arena Pharmaceuticals, Inc.'s (ARNA) CEO Amit Munshi at Wells Fargo Securities 2020 Virtual Healthcare Conference (Transcript)
SAN DIEGO, Sept. 3, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc.
Arena (ARNA) doses first patients in a phase II study evaluating etrasimod in patients with alopecia areata.
Exploring more about medical/pharma side of cannabis sector and thematic ETF investing.
Arena Pharmaceuticals (ARNA) beats bottom-line estimates for the second quarter of 2020. Clinical progress remains on track amid COVID-19 pandemic.
But the company did provide information in its Q2 update that investors should care about.
Arena Pharmaceuticals, Inc. (ARNA) CEO Amit Munshi on Q2 2020 Results - Earnings Call Transcript
Pharma Medical Cannabis More Robust And Resilient (Podcast)
These companies are all surprising a few doubters lately.
SAN DIEGO, June 8, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced changes to its research and development leadership team. Effective June 9, 2020, Dr. Preston ...
A rival's drug validates the biotech's approach.
SAN DIEGO, June 1, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the completion of its previously announced underwritten public offering of 6,325,000 shares o...
Arena Pharmaceuticals, Inc. (ARNA) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
About ARNA
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, a Phase IIb/III clinical trial for Crohn's disease, and a Phase IIb clinical trial for atopic dermatitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; and APD418 that is in Phase ... [Read more...]
| Industry Biotechnology | IPO Date Jul 28, 2000 |
| CEO Amit Munshi | Employees 363 |
| Stock Exchange NASDAQ | Ticker Symbol ARNA |
Analyst Forecasts
According to 14 analysts, the average rating for ARNA stock is "Strong Buy." The 12-month stock price forecast is 94.73, which is an increase of 18.29% from the latest price.